Shanghai-based Viva Biotech Holdings has been awarded the 2025 Asia-Pacific Technology Innovation Leadership Award by Frost & Sullivan, recognizing the company’s pioneering role in AI-powered drug discovery. The honor highlights Viva’s contributions to accelerating early-stage drug development—a field increasingly seen as transformative for global healthcare.
AI at the Core of Drug Discovery
Viva Biotech has integrated artificial intelligence into its structure-based drug discovery platform, enabling researchers to screen vast molecular libraries, predict drug-target interactions, and optimize compounds with greater speed and precision. Traditionally, drug discovery takes years and billions in R&D costs. By leveraging AI, Viva has significantly shortened timelines while boosting hit discovery rates, particularly in complex or hard-to-treat conditions.
Recognition from Frost & Sullivan
The award acknowledges companies that set new benchmarks through technological breakthroughs. Frost & Sullivan praised Viva for combining deep scientific expertise with cutting-edge computational tools, establishing it as a regional leader in intelligent drug discovery. Analysts highlighted Viva’s collaborative model, which connects biotech startups, academic labs, and pharmaceutical partners worldwide.
CEO Statement
Viva Biotech’s CEO welcomed the recognition, stating: “This award validates our commitment to harnessing AI to solve bottlenecks in drug discovery and ultimately bring life-changing therapies to patients faster.”
Industry and Regional Impact
Experts say Viva’s recognition mirrors a global shift in pharma and biotech, where AI adoption is now central to research strategies. From protein structure prediction to AI-driven generative chemistry, digital tools are accelerating progress against cancer, neurodegenerative diseases, and rare genetic conditions. The award also underscores the Asia-Pacific region’s rise as a biotech hub, fueled by government support, cross-border collaborations, and a growing pool of life sciences and AI talent.
AI as a Healthcare Game-Changer
As the pharmaceutical industry grapples with rising R&D costs and pressure to deliver therapies faster, Viva Biotech’s award highlights the growing role of AI as a game-changer in drug development. By offering scalable AI-driven solutions, Viva is not only advancing its own pipeline but also enabling the broader ecosystem to innovate more effectively.
